Abstract
Acute myeloid leukemia is a heterogeneous group of diseases accounting for 15-20% of all tumors diagnosed in children under 15 years of age. The past few decades have yielded remarkable improvements in long-term outcomes for children with acute myeloid leukemia. A better risk-group stratification of patients based upon clinical and biologic features, a more effective use of anti-leukemic agents and enormous improvements in supportive care have increased the probability of cure by approximately 60%. The increase in our understanding of the biology of this disease has resulted in the development of molecularly targeted therapies that are potentially more effective and less toxic than the standard approaches. We here review novel molecularly targeted drugs for the treatment of childhood acute myeloid leukemia such as monoclonal antibodies, inhibitors of signalling molecules, proteasome inhibitors and epigenetic agents. For these recently patented agents, we also provide a detailed analysis of the published preclinical data and the clinical trials that have been completed.
Keywords: Pediatric acute myeloid leukemia, monoclonal antibodies, FMS-Like tyrosin kinase 3 (FLT3) inhibitors, DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, farnesyltransferase Inhibitor, mammalian target, rapamycin (mTOR) inhibitors, epigenetic agents
Recent Patents on Anti-Cancer Drug Discovery
Title: Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Volume: 6 Issue: 3
Author(s): Riccardo Masetti, Katharina Kleinschmidt, Carlotta Biagi and Andrea Pession
Affiliation:
Keywords: Pediatric acute myeloid leukemia, monoclonal antibodies, FMS-Like tyrosin kinase 3 (FLT3) inhibitors, DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, proteasome inhibitors, farnesyltransferase Inhibitor, mammalian target, rapamycin (mTOR) inhibitors, epigenetic agents
Abstract: Acute myeloid leukemia is a heterogeneous group of diseases accounting for 15-20% of all tumors diagnosed in children under 15 years of age. The past few decades have yielded remarkable improvements in long-term outcomes for children with acute myeloid leukemia. A better risk-group stratification of patients based upon clinical and biologic features, a more effective use of anti-leukemic agents and enormous improvements in supportive care have increased the probability of cure by approximately 60%. The increase in our understanding of the biology of this disease has resulted in the development of molecularly targeted therapies that are potentially more effective and less toxic than the standard approaches. We here review novel molecularly targeted drugs for the treatment of childhood acute myeloid leukemia such as monoclonal antibodies, inhibitors of signalling molecules, proteasome inhibitors and epigenetic agents. For these recently patented agents, we also provide a detailed analysis of the published preclinical data and the clinical trials that have been completed.
Export Options
About this article
Cite this article as:
Masetti Riccardo, Kleinschmidt Katharina, Biagi Carlotta and Pession Andrea, Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957775
DOI https://dx.doi.org/10.2174/157489211796957775 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Functional Genomics Approaches in Cancer Research
Current Genomics Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design RAGE and RAGE Ligands in Cancer
Current Molecular Medicine Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) The Potential Roles of Magnetic Resonance Spectroscopy and Perfusion- Weighted Imaging in the Grading of Cerebral Gliomas
Current Medical Imaging Interactions of Cnidarian Toxins with the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry